BackgroundThe objective of this study was to investigate cardiac abnormalities in intensive care unit (ICU) survivors of critical illness and to determine whether temporary acute kidney injury (AKI) is associated with more pronounced findings on cardiovascular magnetic resonance.Methods and ResultsThere were 2175 patients treated in the ICU (from 2015 until 2021) due to critical illness who were screened for study eligibility. Post‐ICU patients without known cardiac disease were prospectively recruited from March 2021 to May 2022. Participants underwent cardiovascular magnetic resonance including assessment of cardiac function, myocardial edema, late gadolinium enhancement, and mapping including extracellular volume fraction. Studentttest, Mann‐WhitneyUtest, and χ2tests were used. There were 48 ICU survivors (46±15 years of age, 28 men, 29 with AKI and continuous kidney replacement therapy, and 19 without AKI) and 20 healthy controls who were included. ICU survivors had elevated markers of myocardial fibrosis (T1: 995±31 ms versus 957±21 ms,P<0.001; extracellular volume fraction: 24.9±2.5% versus 22.8±1.2%,P<0.001; late gadolinium enhancement: 1% [0%–3%] versus 0% [0%–0%],P<0.001), more frequent focal late gadolinium enhancement lesions (21% versus 0%,P=0.03), and an impaired left ventricular function (eg, ejection fraction: 57±6% versus 60±5%,P=0.03; systolic longitudinal strain: 20.3±3.7% versus 23.1±3.5%,P=0.004) compared with healthy controls. ICU survivors with AKI had higher myocardial T1 (1002±33 ms versus 983±21 ms;P=0.046) and extracellular volume fraction values (25.6±2.6% versus 23.9±1.9%;P=0.02) compared with participants without AKI.ConclusionsICU survivors of critical illness without previously diagnosed cardiac disease had distinct abnormalities on cardiovascular magnetic resonance including signs of myocardial fibrosis and systolic dysfunction. Findings were more abnormal in participants who experienced AKI with necessity of continuous kidney replacement therapy during their ICU stay.RegistrationURL:https://www.clinicaltrials.gov; Unique identifier: NCT 05034588.